U.S. Court in Texas Backs FDA’s Removal of Semaglutide from Drug Shortage List
- June 20, 2025
Drug compounders lost their challenge to the Food and Drug Administration’s (FDA’s) decision to remove semaglutide, the active ingredient in Novo Nordisk’s weight loss and diabetes medications Ozempic and Wegovy, from the agency’s drug shortage list.
ARTICLE TAGS
You must be logged in to access this content.